Top Institutional Investors

BVF INC/IL — 13F Holdings & Portfolio

CIK 1056807 · latest 13F-HR filed 2026-08-14

Backtest portfolio

BVF INC/IL manages $3.91B in 13F-reported U.S. long-equity assets across 44 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RVMD (14.20%), KYMR (11.35%), XOMA (8.25%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 7 new positions and exited 4; 18 existing positions rose in reported value and 8 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$3.91B

Long-equity book

Holdings
44

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+7 / −4 / ↑18 / ↓8

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
RVMD14.2% · +4%KYMR11.4% · -30%XOMA8.3% · +193%MLTX8.0% · 0%GHRS5.9% · 0%GPCR4.6% · -3%NKTR4.3% · -7%MIRM3.2% · -33%XNCR2.9% · 0%ALKS2.9% · +8%GLUE2.8% · 0%CGEM2.7% · 0%PVLA2.6% · -30%ZYME2.4% · -2%KURA2.4% · 0%IRON2.2% · -9%STOK2.1% · 0%OLMA1.7% · 0%ANNX1.3% · 0%CBIO1.3% · 0%ACIU1.2% · 0%TYRA1.2% · -25%STRO1.1% · 0%IMCR1.1% · 0%AVTX1.0% · +27%FDMT1.0% · 0%QTTB0.8% · newAVR0.8% · 0%FHTX0.7% · 0%ABSI0.7% · newELDN0.6% · 0%IVVD0.6% · +44%SGMT0.5% · newOKUR0.4% · +64%IMUX0.3% · -90%XFOR0.3% · 0%IMA0.2% · 0%TCRX0.1% · 0%RACC0.1% · newMOLN0.1% · 0%TENX0.1% · 0%ENTX0.1% · newIVA0.1% · 0%ENGNW0.0% · 0%

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 65.6%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Assets Under Management
$6.11B
Discretionary
$6.11B
Employees
13
Accounts
7
Address
44 MONTGOMERY STREET
SUITE 4000
SAN FRANCISCO, CA 94104
Phone
(415) 525-8800
Website
This firm reports 1 disclosure item on its registration.
Name Title / Status Ownership Type
BVF INC. ControlGENERAL PARTNER
since Nov 1993
75% or moreDomestic Entity
KRATKY, JAMES, GEOFFREY ControlCHIEF FINANCIAL OFFICER, CHIEF COMPLIANCE OFFICER
since May 2017
Less than 5%Individual
LAMPERT, MARK, NATHAN ControlCHIEF EXECUTIVE OFFICER
since Nov 1993
Less than 5%Individual
LAMPERT, MARK, NATHAN Control
Indirect owner via BVF INC.
SHAREHOLDER
since Aug 1993
75% or moreIndividual
Ownership & leadership changes · 7 filings with changes since Feb 14, 2012

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 31, 2026 filing
  • No longer listedMCCUNE, JASON, ROBERT · CHIEF OPERATING OFFICER · Less than 5% · control person · listed since Jul 2019
Jan 29, 2024 filing
  • No longer listedPERRY, MATTHEW · PRESIDENT · Less than 5% · control person · listed since Mar 2014
Mar 30, 2020 filing
  • ChangedKRATKY, JAMES, GEOFFREY · title CHIEF COMPLIANCE OFFICER → CHIEF FINANCIAL OFFICER, CHIEF COMPLIANCE OFFICER
Sep 30, 2019 filing
  • No longer listedKAYE, MITCHELL, D · CHIEF OPERATING OFFICER · Less than 5% · control person · listed since Jan 2016
  • AddedMCCUNE, JASON, ROBERT · CHIEF OPERATING OFFICER · Less than 5% · control person
May 4, 2017 filing
  • AddedKRATKY, JAMES, GEOFFREY · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedKAYE, MITCHELL, D · title CHIEF COMPLIANCE OFFICER; CHIEF OPERATING OFFICER → CHIEF OPERATING OFFICER
Mar 29, 2016 filing
  • No longer listedLOY, SPIKE, NASMYTH · CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Jun 2011
  • AddedKAYE, MITCHELL, D · CHIEF COMPLIANCE OFFICER; CHIEF OPERATING OFFICER · Less than 5% · control person
Mar 28, 2014 filing
  • AddedPERRY, MATTHEW · PRESIDENT · Less than 5% · control person
Feb 14, 2012 filing (earliest on record)
  • ListedBVF INC. · GENERAL PARTNER · 75% or more · control person
  • ListedLAMPERT, MARK, NATHAN · CHIEF EXECUTIVE OFFICER · Less than 5% · control person
  • ListedLAMPERT, MARK, NATHAN · SHAREHOLDER · 75% or more · indirect via BVF INC. · control person
  • ListedLOY, SPIKE, NASMYTH · CHIEF COMPLIANCE OFFICER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

BVF INC/IL Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 REVOLUTION MEDICINES INC RVMD 76155X100 $555.3M 14.20% 2,965,160 SH
2 KYMERA THERAPEUTICS INC KYMR 501575104 $444.0M 11.35% 3,872,052 SH
3 XOMA ROYALTY CORPORATION XOMA 98419J206 $322.7M 8.25% 7,593,303 SH
4 MOONLAKE IMMUNOTHERAPEUTICS MLTX 61559X104 $311.5M 7.97% 16,001,284 SH
5 GH RESEARCH PLC GHRS G3855L106 $232.5M 5.95% 8,650,158 SH
6 STRUCTURE THERAPEUTICS INC GPCR 86366E106 $180.7M 4.62% 3,366,823 SH
7 NEKTAR THERAPEUTICS NKTR 640268306 $166.9M 4.27% 2,391,075 SH
8 MIRUM PHARMACEUTICALS INC MIRM 604749101 $123.6M 3.16% 1,056,027 SH
9 XENCOR INC XNCR 98401F105 $114.9M 2.94% 7,133,720 SH
10 ALKERMES PLC ALKS G01767105 $112.9M 2.89% 2,154,704 SH
11 MONTE ROSA THERAPEUTICS INC GLUE 61225M102 $108.0M 2.76% 4,460,886 SH
12 CULLINAN THERAPEUTICS INC CGEM 230031106 $104.7M 2.68% 5,750,683 SH
13 PALVELLA THERAPEUTICS INC NE PVLA 697947109 $102.8M 2.63% 672,789 SH
14 ZYMEWORKS INC ZYME 98985Y108 $95.4M 2.44% 3,649,142 SH
15 KURA ONCOLOGY INC KURA 50127T109 $92.7M 2.37% 8,445,769 SH
16 DISC MEDICINE INC IRON 254604101 $84.4M 2.16% 1,153,612 SH
17 STOKE THERAPEUTICS INC STOK 86150R107 $83.4M 2.13% 2,547,557 SH
18 OLEMA PHARMACEUTICALS INC OLMA 68062P106 $66.3M 1.69% 5,295,893 SH
19 ANNEXON INC ANNX 03589W102 $49.7M 1.27% 8,698,173 SH
20 CRESCENT BIOPHARMA INC. CBIO G2545C104 $49.5M 1.27% 2,748,763 SH
21 AC IMMUNE SA ACIU H00263105 $47.2M 1.21% 19,822,436 SH
22 TYRA BIOSCIENCES INC TYRA 90240B106 $47.1M 1.21% 1,476,196 SH
23 SUTRO BIOPHARMA INC STRO 869367201 $41.6M 1.06% 1,251,788 SH
24 IMMUNOCORE HLDGS PLC IMCR 45258D105 $41.1M 1.05% 1,294,463 SH
25 AVALO THERAPEUTICS INC AVTX 05338F306 $38.4M 0.98% 2,075,545 SH
26 4D MOLECULAR THERAPEUTICS IN FDMT 35104E100 $38.3M 0.98% 2,879,289 SH
27 Q32 BIO INC QTTB 746964105 $29.9M 0.77% 2,350,000 SH
28 ANTERIS TECHNOLOGIES GLOBAL AVR 03675P102 $29.6M 0.76% 3,000,000 SH
29 FOGHORN THERAPEUTICS INC FHTX 344174107 $28.5M 0.73% 5,842,000 SH
30 ABSCI CORPORATION ABSI 00091E109 $27.4M 0.70% 2,361,674 SH
31 ELEDON PHARMACEUTICALS INC ELDN 28617K101 $24.8M 0.63% 6,293,282 SH
32 INVIVYD INC IVVD 00534A102 $24.6M 0.63% 28,165,000 SH
33 SAGIMET BIOSCIENCES INC SGMT 786700104 $19.3M 0.49% 2,500,000 SH
34 ONKURE THERAPEUTICS INC OKUR 68277Q105 $14.8M 0.38% 3,235,778 SH
35 IMMUNIC INC IMUX 4525EP200 $11.8M 0.30% 765,295 SH
36 X4 PHARMACEUTICALS INC XFOR 98420X202 $10.4M 0.27% 2,233,742 SH
37 IMAGENEBIO INC IMA 45175G207 $6.5M 0.17% 1,110,002 SH
38 TSCAN THERAPEUTICS INC TCRX 89854M101 $5.5M 0.14% 5,564,290 SH
39 RESEARCH ALLIANCE CORP III RACC G75226103 $5.3M 0.14% 500,000 SH
40 MOLECULAR PARTNERS AG MOLN 60853G106 $5.1M 0.13% 1,353,968 SH
41 TENAX THERAPEUTICS INC TENX 88032L605 $4.9M 0.13% 339,549 SH
42 ENTERA BIO LTD ENTX M40527109 $4.3M 0.11% 2,425,000 SH
43 INVENTIVA SA IVA 46124U107 $2.6M 0.07% 686,040 SH
44 ENGENE THERAPEUTICS ENGNW 29286X119 $274.1K 0.01% 945,402 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $3.91B 44 0000921895-26-002163
2026-03-31 2026-05-15 $3.14B 41 0000921895-26-001382
2025-12-31 2026-02-17 $2.97B 41 0000921895-26-000449
2025-09-30 2025-11-14 $2.47B 46 0000921895-25-003089
Filer Information
Address
44 MONTGOMERY STREET
40TH FL
SAN FRANCISCO, CA 94104
Phone
(312) 506-6500
Filing Manager
BVF INC/IL
San Francisco, CA
Signatory
Mark N. Lampert
President